Partnering
Contact
Contact Information
Join Us
EN
CN
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
Southeast Asia Business
News
Company News
Partner News
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Home
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
News
Company News
Partner News
Investors
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Partnering
Contact
Contact Information
Join Us
EN
CN
2022-07-08
Won the “Best Pharmaceutical and Medical Company” from Golden Hong Kong Listed Companies
Recognized as the “Honored Company” and the top three of “Best ESG” by the Institutional Investors Magazine
MSCI-ESG rating maintained “AA” for two consecutive years, leading the industry globally
Listed in “CSR Ranking of Pharmaceutical Enterprises in 2020” by Southern Weekly
Awarded the “Most Socially Responsible Listed Company” of Jinqilin Awards held by Sina Finance
2022-07-15
Selected for “Top 25 Listed Pharmaceutical Companies” of “Top 100 Hong Kong Listed Companies”
2022-07-08
Shenzhen Kangzhe was selected for “Shenzhen Top 500 Enterprises” and “Top 100 Corporate Taxpayers in Nanshan District”
Initiated the model of strategic investment in Chinese Biotech; made equity investment in Trinomab and established a joint venture to develop 4 fully human antibody novel drugs
Initiated the model of innovative products customization and entrusted a CRO for customized development of 4 innovative medicines
New Drug Applications of Diazepam Nasal Spray, Tildrakizumab Solution for Injection, and Methotrexate Injection, Pre-filled Syringe (for psoriasis) were accepted by China NMPA
Obtained clinical trial notices of Desidustat Tablets, Methotrexate Injection, Pre-filled Syringe (for RA), and Methylthioninium Chloride Enteric-coated Sustained-release Tablets from China NMPA
CMS Skinhealth, the dermatology and medical aesthetic company, was officially established; acquired three dermatology and medical aesthetic specialty companies including Luqa Ventures, Carnation Medical Technology and Xuli Medical, and achieved collaboration with OVMEDI; acquired assets or products rights of a number of products including Aethoxysklerol, Vmonalisa HA filler, FUBA5200 Focused Ultrasound Body Contouring System and Omega VL Thread Carving Products in Mainland China and/or other countries or regions
